Editor's Note: For Use by Reporters in the European Union Only. JANUVIA(R)(1) (sitagliptin), Merck, Sharp & Dohme's treatment for patients with type 2 diabetes, today received a positive opinion from ...

In one quick announcement Monday, Merck's ($MRK) diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020 ...

Merck & Co’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase-4 inhibitor class – Januvia – is under challenge from three companies – as data presented by ...

Januvia and Janumet are two blockbuster drugs in Merck & Co.’s (MRK) diabetes franchise. The drugs are used to lower the blood sugar level in patients with type-2 diabetes. The combined sales for ...

Merck Sharp & Dohme has won expanded use from the European Commission to market its new diabetes therapy Januvia (sitagliptin). It is the only drug within the DPP-4 class of medicines to have received ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Switching from Merck & Co’s Januvia (sitagliptin) to Novo Nordisk’s Victoza (liraglutide) produced superior blood sugar reductions than continuing with the same treatment, according to latest trial ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the gut’s incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when ...

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history. The problem with uncontrolled diabetes is that it doesn't hurt right away. That's good and bad.

(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales ...